Advances and challenges in hereditary cancer pharmacogenetics

References

• De Mattos-Arruda L, Shen R, Reis-Filho JS, et al. Translating neoadjuvant therapy into survival benefits: one size does not fit all. Nat Rev Clin Oncol. 2016;13:566–579.
   PubMed Web of Science ®Google Scholar
• Wong DJ1, Ribas A2,3. Targeted therapy for melanoma. Cancer Treat Res. 2016;167:251–262.
   PubMedGoogle Scholar
• Carneiro BA1, Kaplan JB, Giles FJ. Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events. Expert Rev Hematol. 2015;8:457–479.
   PubMed Web of Science ®Google Scholar
• Table of Pharmacogenomic Biomarkers in Drug Labeling. Avaliable from: http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm
   Google Scholar
• Relling MV, Klein TE. CPIC: clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin Pharmacol Ther. 2011;89:464–467.
   PubMed Web of Science ®Google Scholar
• Weinshilboum RM. Methylation pharmacogenetics: thiopurine methyltransferase as a model system. Xenobiotica. 1992;22:1055–1071.
   PubMed Web of Science ®Google Scholar
• Schaeffeler E, Fischer C, Brockmeier D, et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-caucasians and identification of novel TPMT variants. Pharmacogenetics. 2004;14:407–417.
   PubMedGoogle Scholar
• Schwab M, Schaffeler E, Marx C, et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics. 2002;12:429–436.
   PubMedGoogle Scholar
• Teml A, Schaeffeler E, Herrlinger KR, et al. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin Pharmacokinet. 2007;46:187–208.
   PubMed Web of Science ®Google Scholar
• Plumpton CO, Roberts D, Pirmohamed M, et al. A systematic review of economic evaluations of pharmacogenetic testing for prevention of adverse drug reactions. Pharmacoeconomics. 2016 Mar 16;34:771–793.
   PubMed Web of Science ®Google Scholar
• Relling MV, Gardner EE, Sandborn WJ, et al. Clinical pharmacogenetics implementation consortium. clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther. 2011;89:387–391.
   PubMed Web of Science ®Google Scholar
• Bosma PJ, Chowdhury JR, Bakker C, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert’s syndrome. N Engl J Med. 1995;333:1171–1175.
   PubMed Web of Science ®Google Scholar
• Hoskins JM, Goldberg RM, Qu P, et al. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst. 2007;99:1290–1295.
   PubMed Web of Science ®Google Scholar
• Etienne-Grimaldi MC, Boyer JC, Thomas F, et al. UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice. Fundam Clin Pharmacol. 2015;29:219–237.
   PubMed Web of Science ®Google Scholar
• Dias MM, Pignon JP, Karapetis CS, et al. The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis. Pharmacogenomics J. 2014;14:424–431.
   PubMed Web of Science ®Google Scholar
• Marcuello E, Páez D, Paré L, et al. A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer. Br J Cancer. 2011;105:53–57.
   PubMed Web of Science ®Google Scholar
• Toffoli G, Sharma MR, Marangon E, et al. Genotype-guided dosing study of FOLFIRI plus bevacizumab in metastatic colorectal cancer patients. Clin Cancer Res. 2016 Aug 9 [ Epub ahead of print].
   PubMedGoogle Scholar
• Gammal RS, Court MH, Haidar CE, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for UGT1A1 and atazanavir prescribing. Clin Pharmacol Ther. 2016;99:363–369.
   PubMed Web of Science ®Google Scholar
• Offer SM, Lee AM, Mattison LK, et al. A DPYD variant (Y186C) in individuals of african ancestry is associated with reduced DPD enzyme activity. Clin Pharmacol Ther. 2013;94:158–166.
   PubMed Web of Science ®Google Scholar
• Offer SM, Fossum CC, Wegner NJ, et al. Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity. Cancer Res. 2014;74:2545–2554.
   PubMed Web of Science ®Google Scholar
• Caudle KE, Thorn CF, Klein TE, et al. Clinical pharmacogenetics implementation consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther. 2013;94:640–645.
   PubMed Web of Science ®Google Scholar
• Wu X, Hawse JR, Subramaniam M, et al. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells. Cancer Res. 2009;69:1722–1727.
   PubMed Web of Science ®Google Scholar
• Goetz MP, Knox SK, Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007;101:113–121.
   PubMed Web of Science ®Google Scholar
• Schroth W, Goetz MP, Hamann U, et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA. 2009;302:1429–1436.
   PubMed Web of Science ®Google Scholar
• de Vries Schultink AH, Zwart W, Linn SC, et al. Effects of pharmacogenetics on the pharmacokinetics and pharmacodynamics of tamoxifen. Clin Pharmacokinet. 2015;54:797–810.
   PubMed Web of Science ®Google Scholar
• Juranka PF, Zastawny RL, Ling V. P-glycoprotein: multidrug-resistance and a superfamily of membrane-associated transport proteins. Faseb J. 1989;3:2583–2592.
   PubMed Web of Science ®Google Scholar
• Bruhn O, Cascorbi I. Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance. Expert Opin Drug Metab Toxicol. 2014;10:1337–1354.
   PubMed Web of Science ®Google Scholar
• Cascorbi I. P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations. Handb Exp Pharmacol. 2011;201:261–283.
   PubMedGoogle Scholar
• Park HS, Lim SM, Shin HJ, et al. Pharmacogenetic analysis of advanced non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin chemotherapy. Pharmacogenet Genomics. 2016;26:116–125.
   PubMed Web of Science ®Google Scholar
• Lamba JK, Fridley BL, Ghosh TM, et al. Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer. Pharmacogenomics. 2014;15:1565–1574.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Chen Q, Zuo D, et al. ABCB1 (rs1128503) polymorphism and response to chemotherapy in patients with malignant tumors-evidences from a meta-analysis. Int J Clin Exp Med. 2015;8:265–272.
   PubMed Web of Science ®Google Scholar
• Takakuwa O, Oguri T, Uemura T, et al. ABCB1 polymorphism as a predictive biomarker for amrubicin-induced neutropenia. Anticancer Res. 2014;34:3517–3522.
   PubMed Web of Science ®Google Scholar
• Ikeda M, Tsuji D, Yamamoto K, et al. Relationship between ABCB1 gene polymorphisms and severe neutropenia in patients with breast cancer treated with doxorubicin/cyclophosphamide chemotherapy. Drug Metab Pharmacokinet. 2015;30:149–153.
   PubMed Web of Science ®Google Scholar
• Vulsteke C, Pfeil AM, Schwenkglenks M, et al. Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel. Breast Cancer Res Treat. 2014;147:557–570.
   PubMed Web of Science ®Google Scholar
• Eckhoff L, Feddersen S, Knoop AS, et al. Docetaxel-induced neuropathy: a pharmacogenetic case-control study of 150 women with early-stage breast cancer. Acta Oncol. 2015;54:530–537.
   PubMed Web of Science ®Google Scholar
• Wu DD, Zhang JX, Li J, et al. Lack of association of the MDR1 C3435T polymorphism with susceptibility to gastric cancer and peptic ulcer: a systemic review and meta-analysis. Asian Pac J Cancer Prev. 2014;15:3021–3027.
   PubMedGoogle Scholar
• Cascorbi I, Haenisch S. Pharmacogenetics of ATP-binding cassette transporters and clinical implications. Methods Mol Biol. 2010;596:95–121.
   PubMedGoogle Scholar
• Megías-Vericat JE, Rojas L, Herrero MJ, et al. Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: a systematic review and meta-analysis of observational studies. Pharmacogenomics J. 2015;15:109–118.
   PubMed Web of Science ®Google Scholar
• Ma CX, Sun YH, Wang HY. ABCB1 polymorphisms correlate with susceptibility to adult acute leukemia and response to high-dose methotrexate. Tumour Biol. 2015;36:7599–7606.
   PubMed Web of Science ®Google Scholar
• Jakobsen Falk I, Fyrberg A, Paul E, et al. Impact of ABCB1 single nucleotide polymorphisms 1236C>T and 2677G>T on overall survival in FLT3 wild-type de novo AML patients with normal karyotype. Br J Haematol. 2014;167:671–680.
   PubMed Web of Science ®Google Scholar
• Gregers J, Gréen H, Christensen IJ, et al. Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2015;15:372–379.
   PubMed Web of Science ®Google Scholar
• Kreile M, Rots D, Piekuse L, et al. Lack of association between polymorphisms in genes MTHFR and MDR1 with risk of childhood acute lymphoblastic leukemia. Asian Pac J Cancer Prev. 2014;15:9707–9711.
   PubMedGoogle Scholar
• Zheng Q, Wu H, Yu Q, et al. ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis. Pharmacogenomics J. 2015;15:127–134.
   PubMed Web of Science ®Google Scholar
• Zu B, Li Y, Wang X, et al. MDR1 gene polymorphisms and imatinib response in chronic myeloid leukemia: a meta-analysis. Pharmacogenomics. 2014;15:667–677.
   PubMed Web of Science ®Google Scholar
• Koo DH, Ryu MH, Ryoo BY, et al. Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor. Cancer Chemother Pharmacol. 2015;75:173–182.
   PubMed Web of Science ®Google Scholar
• Chu YH, Li H, Tan HS, et al. Association of ABCB1 and FLT3 polymorphisms with toxicities and survival in Asian patients receiving sunitinib for renal cell carcinoma. PLoS One. 2015;10:e0134102.
   PubMed Web of Science ®Google Scholar
• Teo YL, Wee HL, Chue XP, et al. Effect of the CYP3A5 and ABCB1 genotype on exposure, clinical response and manifestation of toxicities from sunitinib in Asian patients. Pharmacogenomics J. 2016;16:47–53.
   PubMed Web of Science ®Google Scholar
• Diekstra MH, Swen JJ, Boven E, et al. CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma. Eur Urol. 2015 Oct;68(4):621–629.
   PubMed Web of Science ®Google Scholar
• Beuselinck B, Lambrechts D, Van Brussel T, et al. Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib. Acta Oncol. 2014;53:1413–1422.
   PubMed Web of Science ®Google Scholar
• Misaghian N, Misaghian N1, Ligresti G, et al. Targeting the leukemic stem cell: the holy grail of leukemia therapy. Leukemia. 2009;23:25–42.
   PubMed Web of Science ®Google Scholar
• Imai Y, Nakane M, Kage K, et al. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther. 2002;1:611–616.
   PubMed Web of Science ®Google Scholar
• Delord M, Rousselot P, Cayuela JM, et al. High imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patients. Oncotarget. 2013;4:1582–1591.
   PubMed Web of Science ®Google Scholar
• Salimizand H, Amini S, Abdi M, et al. Concurrent effects of ABCB1 C3435T, ABCG2 C421A, and XRCC1 Arg194Trp genetic polymorphisms with risk of cancer, clinical output, and response to treatment with imatinib mesylate in patients with chronic myeloid leukemia. Tumour Biol. 2016;37:791–798.
   PubMed Web of Science ®Google Scholar
• Chen X, Chen D, Yang S, et al. Impact of ABCG2 polymorphisms on the clinical outcome of TKIs therapy in Chinese advanced non-small-cell lung cancer patients. Cancer Cell Int. 2015;15:43.
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Sato K, Niioka T, et al. Relationship among gefitinib exposure, polymorphisms of its metabolizing enzymes and transporters, and side effects in Japanese patients with non-small-cell lung cancer. Clin Lung Cancer. 2015;16:274–281.
   PubMed Web of Science ®Google Scholar
• Vulsteke C, Lambrechts D, Dieudonné A, et al. Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC). Ann Oncol. 2013;24:1513–1525.
   PubMed Web of Science ®Google Scholar
• Au A, Baba AA, Azlan H, et al. Clinical impact of ABCC1 and ABCC2 genotypes and haplotypes in mediating imatinib resistance among chronic myeloid leukaemia patients. J Clin Pharm Ther. 2014;39:685–690.
   PubMed Web of Science ®Google Scholar
• Lopez-Lopez E, Ballesteros J, Piñan MA, et al. Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia. Pharmacogenet Genomics. 2013;23:53–61.
   PubMedGoogle Scholar
• Cuffe S, Azad AK, Qiu X, et al. ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients. Cancer Epidemiol. 2016;41:50–56.
   PubMed Web of Science ®Google Scholar
• Lambrechts S, Lambrechts D, Despierre E, et al. Belgian and Luxembourg Gynaecological Oncology Group (BGOG). genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer. BMC Pharmacol Toxicol. 2015;16:2.
   PubMed Web of Science ®Google Scholar
• Chen X, Jiang M, Zhao RK, et al. Quantitative assessment of the association between ABC polymorphisms and osteosarcoma response: a meta-analysis. Asian Pac J Cancer Prev. 2015;16:4659–4664.
   PubMedGoogle Scholar
• Ruzzo A, Graziano F, Galli F, et al. Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients. Sci Rep. 2014;4:6828.
   PubMed Web of Science ®Google Scholar
• Choi JR, Kim JO, Kang DR, et al. Genetic variations of drug transporters can influence on drug response in patients treated with docetaxel chemotherapy. Cancer Res Treat. 2015;47:509–517.
   PubMedGoogle Scholar
• Thomas J, Wang L, Clark RE, et al. Active transport of imatinib into and out of cells: implications for drug resistance. Blood. 2004;104:3739–3745.
   PubMed Web of Science ®Google Scholar
• White DL, Saunders VA, Dang P, et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood. 2006;108:697–704.
   PubMed Web of Science ®Google Scholar
• Nies AT1, Schaeffeler E, van Der Kuip H, et al. Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1). Clin Cancer Res. 2014;20:985–994.
   PubMed Web of Science ®Google Scholar
• Grinfeld J, Gerrard G, Alikian M, et al. A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia. Br J Haematol. 2013;163:631–639.
   PubMed Web of Science ®Google Scholar
• Koren-Michowitz M, Buzaglo Z, Ribakovsky E, et al. OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients. Eur J Haematol. 2014;92:283–288.
   PubMed Web of Science ®Google Scholar
• Vine J, Cohen SB, Ruchlemer R, et al. Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia. Leuk Lymphoma. 2014;55:2525–2531.
   PubMed Web of Science ®Google Scholar
• Watkins DB, Hughes TP, White DL. OCT1 and imatinib transport in CML: is it clinically relevant? Leukemia. 2015;29:1960–1969.
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M, Cascorbi I. Pharmacogenomic or -epigenomic biomarkers in drug treatment: Two sides of the same medal? Clin Pharmacol Ther. 2016;99:478–480.
   PubMed Web of Science ®Google Scholar
• Haenisch S, Werk AN, Cascorbi I. MicroRNAs and their relevance to ABC transporters. Br J Clin Pharmacol. 2014;77:587–596.
   PubMed Web of Science ®Google Scholar
• Werk AN, Bruckmueller H, Haenisch S, et al. Genetic variants may play an important role in mRNA-miRNA interaction: evidence for haplotype-dependent downregulation of ABCC2 (MRP2) by miRNA-379. Pharmacogenet Genomics. 2014;24:283–291.
   PubMed Web of Science ®Google Scholar
• Lynch TJ1, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–2139.
   PubMed Web of Science ®Google Scholar
• Diouf B, Crews KR, Lew G, et al. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA. 2015;313:815–823.
   PubMed Web of Science ®Google Scholar
• Doherty M, Metcalfe T, Guardino E, et al. Precision medicine and oncology: an overview of the opportunities presented by next-generation sequencing and big data and the challenges posed to conventional drug development and regulatory approval pathways. Ann Oncol. 2016;27:1644–1646.
   PubMed Web of Science ®Google Scholar